Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Current Quarter	$-0.09	Next Quarter	$-0.09
Current Year	$-0.46	Next Year	$-0.42
QoQ Growth	+0.0%	YoY Growth	+8.7%
3Y EPS CAGR	-30.2%	Target Price	$4.50
Consensus	Buy	Upside	+221.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OVID	$1.40	+14.75%	1.30M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OVID	$1.40	+14.8%	1.30M
3
4
5
6

OVID

OVID

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Ovid Therapeutics Inc. Data in Excel

Get Ovid Therapeutics Inc. Data in Excel